Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines

Genome Biology

Volumn 15, Issue 3, 2014, Pages

  Geeleher, Paul ^a   Cox, Nancy J ^a   Huang, R Stephanie ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; DOCETAXEL; ERLOTINIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; BREAST CANCER; CELL LINE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION; IN VITRO STUDY; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MATHEMATICAL MODEL; MYELOMA; PREDICTION; ALGORITHM; BIOLOGICAL MODEL; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; EVALUATION STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HUMAN GENOME; METABOLISM; MULTIPLE MYELOMA; PREDICTIVE VALUE; TUMOR CELL LINE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MODELS, GENETIC; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84897951842     PISSN: None     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/gb-2014-15-3-r47     Document Type: Article

References (57)

1. Mishra A, Verma M. Cancer biomarkers: are we ready for the prime time?. Cancers (Basel) 2010, 2:190-208. 10.3390/cancers2010190, 3827599, 24281040.
2. Jiang Y, Wang M. Personalized medicine in oncology: tailoring the right drug to the right patient. Biomark Med 2010, 4:523-533. 10.2217/bmm.10.66, 20701441.
3. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013, 12:358-369. 10.1038/nrd3979, 23629504.
4. Sawyers CL. The cancer biomarker problem. Nature 2008, 452:548-552. 10.1038/nature06913, 18385728.
5. Lee SH, Van Der Werf JHJ, Hayes BJ, Goddard ME, Visscher PM. Predicting unobserved phenotypes for complex traits from whole-genome SNP data. PLoS Genet 2008, 4:e1000231. 10.1371/journal.pgen.1000231, 2565502, 18949033.
6. Ober U, Ayroles JF, Stone EA, Richards S, Zhu D, Gibbs RA, Stricker C, Gianola D, Schlather M, Mackay TFC, Simianer H. Using whole-genome sequence data to predict quantitative trait phenotypes in Drosophila melanogaster. PLoS Genet 2012, 8:e1002685. 10.1371/journal.pgen.1002685, 3342952, 22570636.
7. Adey A, Burton JN, Kitzman JO, Hiatt JB, Lewis AP, Martin BK, Qiu R, Lee C, Shendure J. The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line. Nature 2013, 500:207-211. 10.1038/nature12064, 3740412, 23925245.
8. Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967, 12490681.
9. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262-272. 10.1093/jnci/djj052, 16478745.
10. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu T-M, Goodsaid FM, Pusztai L, Shaughnessy JD, Oberthuer A, Thomas RS, Paules RS, Fielden M, Barlogie B, Chen W, Du P, Fischer M, Furlanello C, Gallas BD, Ge X, Megherbi DB, Symmans WF, Wang MD, Zhang J, Bitter H, Brors B, Bushel PR, Bylesjo M, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010, 28:827-838. 10.1038/nbt.1665, 3315840, 20676074.
11. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman D, Jensen RV, Johnson CD, Lobenhofer EK, Puri RK, Schrf U, Thierry-Mieg J, Wang C, Wilson M, Wolber PK, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006, 24:1151-1161. 10.1038/nbt1239, 3272078, 16964229.
12. Rudy J, Valafar F. Empirical comparison of cross-platform normalization methods for gene expression data. BMC Bioinformatics 2011, 12:467. 10.1186/1471-2105-12-467, 3314675, 22151536.
13. Van Wieringen WN, Kun D, Hampel R, Boulesteix A-L. Survival prediction using gene expression data: a review and comparison. Comput Stat Data Anal 2009, 53:1590-1603.
14. Bøvelstad HM, Nygård S, Størvold HL, Aldrin M, Borgan T, Frigessi A, Lingjaerde OC. Predicting survival from microarray data - a comparative study. Bioinformatics 2007, 23:2080-2087. 10.1093/bioinformatics/btm305, 17553857.
15. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575. 10.1038/nature11005, 3349233, 22460902.
16. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P, de Silva M, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607. 10.1038/nature11003, 3320027, 22460905.
17. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJG, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013, 19:279-290. 10.1158/1078-0432.CCR-12-1558, 3567921, 23091115.
18. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003, 362:362-369. 10.1016/S0140-6736(03)14023-8, 12907009.
19. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD, Bergsagel PL, Schenkein D, Esseltine D-L, Boral A, Anderson KC. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007, 109:3177-3188. 10.1182/blood-2006-09-044974, 17185464.
20. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong C-O, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28:1145-1153. 10.1200/JCO.2009.22.4725, 2834466, 20100965.
21. Breiman L. Random forests. Mach Learn 2001, 45:5-32.
22. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002, 99:6567-6572. 10.1073/pnas.082099299, 124443, 12011421.
23. Jolliffe IT. A note on the use of principal components in regression. Appl Stat 1982, 31:300.
24. Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc 1994, 58:267-288.
25. Hui Zou TH. Regularization and variable selection via the elastic net. J R Stat Soc 2005, 67:301-320.
26. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264. 10.1093/biostatistics/4.2.249, 12925520.
27. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005, 33:e175. 10.1093/nar/gni179, 1283542, 16284200.
28. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005, 21:3940-3941. 10.1093/bioinformatics/bti623, 16096348.
29. Fawcett T. ROC Graphs: Notes and Practical Considerations for Researchers 2004,
30. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
31. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123. 10.1046/j.1365-2141.1998.00930.x, 9753033.
32. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003, 100:9991-9996. 10.1073/pnas.1732008100, 187912, 12900505.
33. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006, 25:127-141. 10.1002/sim.2331, 16217841.
34. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011, 1:44-53. 10.1158/2159-8274.CD-10-0010, 22586319.
35. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909. 10.1200/JCO.2005.02.857, 16043828.
36. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314, 15118125.
37. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139. 10.1056/NEJMoa040938, 15118073.
38. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028. 10.1182/blood-2005-11-013458, 1895543, 16728703.
39. Agnelli L, Bicciato S, Mattioli M, Fabris S, Intini D, Verdelli D, Baldini L, Morabito F, Callea V, Lombardi L, Neri A. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 2005, 23:7296-7306. 10.1200/JCO.2005.01.3870, 16129847.
40. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee J-S, Tellez MS, Tan P. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011, 141:476-85-485. e1-11, 3152688, 21684283.
41. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, Nguyen C, Xerri L, Houlgatte R, Jacquemier J, Viens P, Birnbaum D. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005, 65:2170-2178. 10.1158/0008-5472.CAN-04-4115, 15781628.
42. Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi M-C, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Fléjou J-F, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 2013, 10:e1001453. 10.1371/journal.pmed.1001453, 3660251, 23700391.
43. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004, 101:811-816. 10.1073/pnas.0304146101, 321763, 14711987.
44. Xu X, Zhang Y, Williams J, Antoniou E, McCombie WR, Wu S, Zhu W, Davidson NO, Denoya P, Li E. Parallel comparison of Illumina RNA-Seq and Affymetrix microarray platforms on transcriptomic profiles generated from 5-aza-deoxy-cytidine treated HT-29 colon cancer cells and simulated datasets. BMC Bioinformatics 2013, 14:S1.
45. 't Hoen PAC, Friedländer MR, Almlöf J, Sammeth M, Pulyakhina I, Anvar SY, Laros JFJ, Buermans HPJ, Karlberg O, Brännvall M, van Ommen G-JB, Estivill X, Guigó R, Syvänen A-C, Gut IG, Dermitzakis ET, Antonorakis SE, Brazma A, Flicek P, Schreiber S, Rosenstiel P, Meitinger T, Strom TM, Lehrach H, Sudbrak R, Carracedo A, van Iterson M, Monlong J, Lizano E, Bertier G, et al. Reproducibility of high-throughput mRNA and small RNA sequencing across laboratories. Nat Biotechnol 2013, 31:1015-1022. 10.1038/nbt.2702, 24037425.
46. Wheeler HE, Aquino-Michaels K, Gamazon ER, Trubetskoy VV, Dolan ME, Huang RS, Cox NJ, Im HK. Poly-omic prediction of complex traits: OmicKriging 2013,
47. Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I, Busund L-T. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 2011, 6:209-217. 10.1097/JTO.0b013e3181f8a1bd, 21107292.
48. Zhang CH, Zhang YP. Maximizing the commercial value of personalized therapeutics and companion diagnostics. Nat Biotechnol 2013, 31:803-805. 10.1038/nbt.2679, 24022154.
49. Menden MP, Iorio F, Garnett M, McDermott U, Benes CH, Ballester PJ, Saez-Rodriguez J. Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS One 2013, 8:e61318. 10.1371/journal.pone.0061318, 3640019, 23646105.
50. Team RDC R: A Language and Environment for Statistical Computing 2008, Austria, Vienna, Team RDC.
51. Leisch F. Dynamic generation of statistical reports using literate data analysis. Proc Comput Stat 2002, 575-580. http://link.springer.com/chapter/10.1007%2F978-3-642-57489-4_89#.
52. The cancer genome project. http://www.cancerrxgene.org.
53. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20:307-315. 10.1093/bioinformatics/btg405, 14960456.
54. Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics 2007, 23:1846-1847. 10.1093/bioinformatics/btm254, 17496320.
55. Cule E, De Iorio M. Ridge regression in prediction problems: automatic choice of the ridge parameter. Genet Epidemiol 2013, 37:704-714. 10.1002/gepi.21750, 23893343.
56. Gentleman R, Carey V, Huber W, Hahne F. genefilter: methods for filtering genes from microarray experiments. http://cobra20.fhcrc.org/packages/release/bioc/html/genefilter.html.
57. University of Chicago GeneMed Server. http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/.